ASXL2

ASXL2 is an epigenetic scaffold protein that integrates Polycomb and Trithorax group functions to regulate lineage-specific gene expression across hematopoietic, skeletal, cardiac, metabolic, and germline contexts. ASXL2 forms a mutually exclusive deubiquitinase complex with BAP1 via its ASXM domain, generating a composite ubiquitin-binding interface that promotes H2A Lys-119 deubiquitination, and independently recruits MLL3/COMPASS to enhancers of tumor suppressor genes—an interaction negatively regulated by CARM1-mediated methylation at R639/R641 (PMID:26416890, PMID:36197977). Through its PHD finger, which preferentially binds dimethylated H3K4, ASXL2 also interacts with nuclear receptors (ERα, PPARγ, LXRα) and chromatin modifiers (EZH2, LSD1, UTX, MLL2) to coordinate activating and repressive histone marks at target promoters and enhancers (PMID:26640146, PMID:26051940, PMID:23046516). Loss of ASXL2 in mice causes haploinsufficient tumor-suppressor defects including enhanced AML1-ETO leukemogenesis and MDS-like disease through increased chromatin accessibility at leukemogenic loci, osteopetrosis via failed osteoclast differentiation, dilated cardiomyopathy with derepression of β-MHC, and resistance to diet-induced obesity through macrophage-intrinsic regulation of catecholamine degradation (PMID:28516957, PMID:28593990, PMID:19270745, PMID:32310225).

1. 2009 High

   The first in vivo evidence that ASXL2 has dual Polycomb/Trithorax functions came from knockout mice showing reduced H3K27me3 and bidirectional homeotic transformations, establishing ASXL2 as a chromatin regulator rather than a purely Polycomb group factor.

   Evidence Gene-trap Asxl2−/− mouse with histone modification analysis and skeletal phenotyping

   PMID:19270745

   Open questions at the time

   • No biochemical mechanism for H3K27me3 regulation defined
   • Chromatin modifier partners not yet identified
   • Tissue-specific versus global role unclear
2. 2011 High

   ASXL2 was shown to be required for osteoclastogenesis, extending its physiological roles beyond axial patterning to bone remodeling.

   Evidence siRNA knockdown in bone marrow macrophages and Asxl2 knockout mouse with bone mineral density measurement

   PMID:21490954

   Open questions at the time

   • Downstream chromatin targets in osteoclasts not mapped
   • Mechanism linking ASXL2 to osteoclast transcriptional programs unknown
3. 2012 Medium

   The cardiac requirement for ASXL2 was established and linked to EZH2 co-occupancy at the β-MHC promoter, providing the first evidence that ASXL2 directly recruits a Polycomb methyltransferase to a specific locus.

   Evidence Asxl2−/− mouse echocardiography and ChIP at β-MHC promoter

   PMID:23046516

   Open questions at the time

   • Direct physical interaction between ASXL2 and EZH2 not demonstrated at this stage
   • Whether ASXL2 recruits the entire PRC2 complex or only EZH2 is unresolved
   • Single promoter examined
4. 2013 Medium

   ASXL2 was found to coactivate LXRα-dependent transcription in a ligand-dependent manner, revealing a nuclear receptor coregulator function opposing ASXL1.

   Evidence Co-immunoprecipitation, ChIP at ABCA1 promoter, siRNA knockdown with lipid accumulation assay

   PMID:24321552

   Open questions at the time

   • Mechanism of transcriptional activation at LXRα targets (histone marks, cofactor recruitment) not defined
   • In vivo metabolic significance not tested
5. 2015 High

   The molecular basis of ASXL2-BAP1 deubiquitinase activity was resolved: ASXL2's ASXM domain binds the BAP1 CTD to form a composite ubiquitin-binding interface essential for H2AK119 deubiquitination, and BAP1 reciprocally stabilizes ASXL2 protein—establishing the core enzymatic mechanism and explaining why BAP1 cancer mutations destabilize ASXL2.

   Evidence Reconstituted in vitro DUB assays, reciprocal co-IP, active-site and domain mutagenesis including cancer-associated mutations, senescence assays

   PMID:26416890

   Open questions at the time

   • Structural resolution of the CUBI interface lacking
   • How BAP1-ASXL2 versus BAP1-ASXL1 complexes achieve target specificity unknown
6. 2015 High

   ASXL2 was simultaneously shown to interact with PPARγ to drive osteoclast differentiation through two genetically separable pathways (PPARγ/c-Fos for formation; PGC-1β for mitochondrial biogenesis), and with ERα plus histone modifiers (LSD1, UTX, MLL2) at estrogen-responsive promoters via its H3K4me2-binding PHD finger—defining ASXL2 as a versatile nuclear receptor coregulator and reader of histone methylation.

   Evidence ASXL2−/− mice with osteoclast assays and genetic epistasis; co-IP with ERα/LSD1/UTX/MLL2, ChIP-seq, PHD finger binding assay, MCF7 xenografts

   PMID:26051940 PMID:26640146

   Open questions at the time

   • Whether PHD finger reading of H3K4me2 is required for all ASXL2 genomic occupancy untested
   • Structural basis of ERα versus PPARγ selectivity unknown
7. 2017 High

   Two independent studies demonstrated that ASXL2 loss enhances hematopoietic stem cell self-renewal and promotes myeloid malignancy (AML with AML1-ETO; MDS), acting as a haploinsufficient tumor suppressor that restricts chromatin accessibility at leukemogenic enhancers and maintains proper H3K27ac/H3K4me1-2 balance.

   Evidence Conditional Asxl2 knockout mice, bone marrow transplantation, ATAC-seq, paired daughter cell assays, histone modification profiling

   PMID:28516957 PMID:28593990

   Open questions at the time

   • Direct mechanistic link between BAP1-ASXL2 DUB activity and chromatin accessibility changes not established
   • Whether ASXL2's tumor-suppressor function requires MLL3 recruitment or only BAP1-dependent H2A deubiquitination is unclear
8. 2020 High

   A macrophage-intrinsic metabolic role for ASXL2 was uncovered: myeloid-specific deletion protects against diet-induced obesity by suppressing catecholamine degradation, thereby preserving brown adipose tissue thermogenesis.

   Evidence Myeloid-specific conditional knockout (LysM-Cre), metabolic phenotyping, in vivo nanoparticle siRNA validation

   PMID:32310225

   Open questions at the time

   • Chromatin targets in macrophages that control catecholamine degradation genes not mapped
   • Whether this metabolic role depends on BAP1 complex activity unknown
9. 2022 High

   The BAP1-ASXL2 complex was shown to directly recruit MLL3/COMPASS to enhancers of tumor suppressor genes, and CARM1-mediated methylation of ASXL2 at R639/R641 was identified as a regulatory switch that disrupts this interaction—linking arginine methylation to epigenetic enhancer programming.

   Evidence Co-IP, ChIP-seq, ASXL2 KO, in vitro methylation assay, site-directed mutagenesis

   PMID:36197977

   Open questions at the time

   • Whether CARM1-dependent regulation occurs at all ASXL2-dependent enhancers or a subset is unknown
   • No structural detail on how methylation blocks MLL3 binding
10. 2025 Medium

    ASXL2 was shown to promote osteogenic differentiation of human periodontal ligament stem cells by maintaining activating H3K4me3 and reducing repressive H2AK119ub/H3K27me3 at osteogenic loci, extending its bone-regulatory role to human mesenchymal stem cell contexts.

    Evidence Lentiviral ASXL2 knockdown with ALP activity, mineralization assays, histone modification analysis

    PMID:40680514

    Open questions at the time

    • Specific genomic loci affected not mapped by ChIP-seq
    • Whether BAP1 complex mediates the H2AK119ub changes in this context not tested
11. 2026 Medium

    ASXL2 was linked to spermatogenesis: it recruits EZH2 to the CEP162 promoter to deposit H3K27me3 and repress CEP162 transcription, with hypoxia-induced ASXL2 loss leading to axonemal microtubule destabilization in spermatids.

    Evidence ASXL2 knockdown/overexpression in spermatocytes, ChIP at CEP162 promoter, co-IP of ASXL2-EZH2

    PMID:41782374

    Open questions at the time

    • Genome-wide EZH2 targets dependent on ASXL2 in germ cells not mapped
    • Whether BAP1 is involved in this germline function unknown
    • Single target gene examined

• Key unresolved questions include how target specificity between BAP1-ASXL1 and BAP1-ASXL2 complexes is achieved genome-wide, whether ASXL2's tumor-suppressor function depends primarily on BAP1-mediated H2A deubiquitination or MLL3 recruitment, and how CARM1-dependent regulation integrates with nuclear receptor coactivation.
• No structural model of the full-length ASXL2 protein or its complexes
• Genome-wide discrimination between BAP1-ASXL1 and BAP1-ASXL2 targets not mapped in most tissues
• Whether ASXL2's metabolic, cardiac, and germline functions are BAP1-dependent remains untested